NASDAQ:MGNXMacroGenics Stock Price, Forecast & News

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MGNX stock has increased by 290.9% and is now trading at $25.37. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for MacroGenics.

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.10. The biopharmaceutical company earned $13.68 million during the quarter, compared to analysts' expectations of $7.43 million. MacroGenics had a negative net margin of 222.14% and a negative return on equity of 62.43%. View MacroGenics' earnings history.

13 brokerages have issued 1 year target prices for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' share price to reach $23.67 in the next twelve months. This suggests that the stock has a possible downside of 6.7%. View analysts' price targets for MacroGenics.

News articles about MGNX stock have trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MacroGenics earned a news impact score of -2.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutMacroGenics.

MacroGenics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,860,000 shares, a drop of 11.2% from the April 30th total of 3,220,000 shares. Based on an average trading volume of 2,620,000 shares, the short-interest ratio is currently 1.1 days. Currently, 6.6% of the company's stock are sold short. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Forty Seven (FTSV), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO) and Arrowhead Pharmaceuticals (ARWR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Bausch Health Companies (BHC), Epizyme (EPZM), Incyte (INCY), Karyopharm Therapeutics (KPTI) and Nektar Therapeutics (NKTR).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.72%), Invesco Ltd. (9.12%), Wasatch Advisors Inc. (5.32%), State Street Corp (3.90%), Rhenman & Partners Asset Management AB (2.04%) and Nuveen Asset Management LLC (1.81%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Morgan Stanley, Spark Investment Management LLC, Principal Financial Group Inc., Two Sigma Investments LP, Deutsche Bank AG, and GSA Capital Partners LLP. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, and Thomas Spitznagel. View insider buying and selling activity for MacroGenics.

MGNX stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Nuveen Asset Management LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Thrivent Financial for Lutherans, BlackRock Inc., and Geode Capital Management LLC. View insider buying and selling activity for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $25.37.

MacroGenics has a market capitalization of $1.25 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe.

The official website for MacroGenics is www.macrogenics.com.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.